AU2017239348B2 - Substituted-indole compounds as estrogen receptor down-regulators - Google Patents

Substituted-indole compounds as estrogen receptor down-regulators Download PDF

Info

Publication number
AU2017239348B2
AU2017239348B2 AU2017239348A AU2017239348A AU2017239348B2 AU 2017239348 B2 AU2017239348 B2 AU 2017239348B2 AU 2017239348 A AU2017239348 A AU 2017239348A AU 2017239348 A AU2017239348 A AU 2017239348A AU 2017239348 B2 AU2017239348 B2 AU 2017239348B2
Authority
AU
Australia
Prior art keywords
compound
group
cooh
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017239348A
Other languages
English (en)
Other versions
AU2017239348A1 (en
Inventor
Shuhui Chen
Charles Z. Ding
Jiaqiang Dong
Huijun HE
Lihong Hu
Jianyu LU
Tie-Lin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luoxin Healthcare Science And Technology Development Beijing Ltd
Original Assignee
Luoxin Healthcare Science And Tech Development Beijing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luoxin Healthcare Science And Tech Development Beijing Ltd filed Critical Luoxin Healthcare Science And Tech Development Beijing Ltd
Publication of AU2017239348A1 publication Critical patent/AU2017239348A1/en
Assigned to SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD., Luoxin Pharmaceutical (Shanghai) Co., Ltd. reassignment SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. Amend patent request/document other than specification (104) Assignors: LUOXIN BIOTECHNOLOGY (SHANGHAI) CO., LTD, SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
Application granted granted Critical
Publication of AU2017239348B2 publication Critical patent/AU2017239348B2/en
Assigned to Luoxin Healthcare Science and Technology Development (Beijing) Ltd. reassignment Luoxin Healthcare Science and Technology Development (Beijing) Ltd. Request for Assignment Assignors: Luoxin Pharmaceutical (Shanghai) Co., Ltd., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
AU2017239348A 2016-03-25 2017-03-24 Substituted-indole compounds as estrogen receptor down-regulators Active AU2017239348B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610180518 2016-03-25
CN201610180518.7 2016-03-25
CN201610867918.5 2016-09-29
CN201610867918 2016-09-29
PCT/CN2017/078139 WO2017162206A1 (zh) 2016-03-25 2017-03-24 作为雌激素受体降解剂的吲哚并取代哌啶类化合物

Publications (2)

Publication Number Publication Date
AU2017239348A1 AU2017239348A1 (en) 2018-11-15
AU2017239348B2 true AU2017239348B2 (en) 2020-03-12

Family

ID=59899253

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017239348A Active AU2017239348B2 (en) 2016-03-25 2017-03-24 Substituted-indole compounds as estrogen receptor down-regulators

Country Status (11)

Country Link
US (1) US10519143B2 (cg-RX-API-DMAC10.html)
EP (1) EP3434668B1 (cg-RX-API-DMAC10.html)
JP (1) JP6790222B2 (cg-RX-API-DMAC10.html)
KR (1) KR102111792B1 (cg-RX-API-DMAC10.html)
CN (1) CN108884035B (cg-RX-API-DMAC10.html)
AU (1) AU2017239348B2 (cg-RX-API-DMAC10.html)
CA (1) CA3018801C (cg-RX-API-DMAC10.html)
ES (1) ES2821407T3 (cg-RX-API-DMAC10.html)
RU (1) RU2722441C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201808363TA (cg-RX-API-DMAC10.html)
WO (1) WO2017162206A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032627B (zh) 2017-09-25 2023-10-20 罗欣健康科技发展(北京)有限公司 一种雌激素受体抑制剂的晶型及其制备方法
AU2019321588C1 (en) 2018-08-17 2026-05-14 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
EP3889136B1 (en) * 2018-11-28 2024-12-18 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor
AU2019400398B2 (en) * 2018-12-17 2024-10-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Estrogen receptor antagonist
CN116891461B (zh) * 2022-03-30 2026-05-15 罗欣药业(上海)有限公司 一种serd中间体的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012037411A2 (en) * 2010-09-16 2012-03-22 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
US9499538B2 (en) * 2012-03-20 2016-11-22 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
SG11201607334YA (en) * 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
MA39740A (fr) * 2014-03-13 2017-01-18 Hoffmann La Roche Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012037411A2 (en) * 2010-09-16 2012-03-22 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof

Also Published As

Publication number Publication date
CA3018801A1 (en) 2017-09-28
RU2018135203A3 (cg-RX-API-DMAC10.html) 2020-04-27
RU2722441C2 (ru) 2020-06-01
CN108884035A (zh) 2018-11-23
US20190106414A1 (en) 2019-04-11
ES2821407T3 (es) 2021-04-26
SG11201808363TA (en) 2018-10-30
US10519143B2 (en) 2019-12-31
EP3434668B1 (en) 2020-08-26
RU2018135203A (ru) 2020-04-27
EP3434668A4 (en) 2019-08-14
ES2821407T8 (es) 2022-02-02
CN108884035B (zh) 2020-03-13
WO2017162206A1 (zh) 2017-09-28
EP3434668A1 (en) 2019-01-30
KR102111792B1 (ko) 2020-05-18
JP2019512550A (ja) 2019-05-16
JP6790222B2 (ja) 2020-11-25
CA3018801C (en) 2020-06-23
KR20180128456A (ko) 2018-12-03
HK1256936A1 (zh) 2019-10-04
AU2017239348A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
CN110446712A (zh) 作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
WO2019085933A1 (zh) 作为Wee1抑制剂的大环类化合物及其应用
EP3434668B1 (en) Indolo-substituted-piperidine compounds as estrogen receptor degrading agent
KR100250922B1 (ko) 교감신경 흥분 및 항빈뇨 활성을 갖는 에탄올아민 유도체
CN110382463B (zh) Hdac6选择性抑制剂及其制备方法和应用
CN110139863B (zh) 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
WO2022166879A1 (zh) 苯并七元环类双功能化合物及其应用
EP3686199B9 (en) Fused ring derivative as a2a receptor inhibitor
WO2024213032A1 (zh) 一种吲哚类化合物及其制备方法与应用
WO2001044187A1 (en) Novel substituted tricyclic compounds
EP3502099A1 (en) Cyclic compound acting as pde4 inhibitor
TWI810344B (zh) 氮雜環丁烷衍生物的硼酸酯
WO2023011608A1 (zh) 含三并环类衍生物调节剂、其制备方法和应用
RU2832735C9 (ru) Антагонист эстрогенового рецептора
RU2832735C2 (ru) Антагонист эстрогенового рецептора
HK1256936B (en) Substituted-indole compounds as estrogen receptor down-regulators
CN111868032B (zh) 犬尿氨酸通路抑制剂
CA3122621A1 (en) Estrogen receptor antagonist
RU2772274C2 (ru) Селективные ингибиторы hdac6, способ их получения и их применение
WO2022228317A1 (zh) 哌嗪衍生物及其应用
HK40025623A (en) Fused ring derivative as a2a receptor inhibitor
HK40009263B (en) Azetidine derivative
HK40022836B (en) Macrocyclic compound as a wee1 inhibitor and applications thereof
HK40009413B (en) Hdac6 selective inhibitors, preparation method therefor, and application thereof
HK40009413A (en) Hdac6 selective inhibitors, preparation method therefor, and application thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ SUBSTITUTED-INDOLE COMPOUNDS AS ESTROGEN RECEPTOR DOWN-REGULATORS

HB Alteration of name in register

Owner name: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD.

Free format text: FORMER NAME(S): LUOXIN BIOTECHNOLOGY (SHANGHAI) CO., LTD; SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.

Owner name: SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LT

Free format text: FORMER NAME(S): LUOXIN BIOTECHNOLOGY (SHANGHAI) CO., LTD; SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: LUOXIN HEALTHCARE SCIENCE AND TECHNOLOGY DEVELOPMENT (BEIJING) LTD.

Free format text: FORMER OWNER(S): SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.; LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD.